Skip to main content

Novartis Ag ADR(NVS-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low147.77
Day High149.63
Open:149.61
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Better Pharma Dividend Stock: Novartis vs. Merck
Tipranks
3 Best Vanguard Dividend ETFs for Reliable Passive Income in 2026
Tipranks
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
Tipranks
Citi Reaffirms Their Buy Rating on Novartis AG (NOVN)
MarketBeat
3 Low-Volatility ETFs for Peace of Mind in Turbulent Times
MarketBeat.com
Tipranks
Novartis AG (NOVN) Gets a Hold from UBS
Zacks Investment Research
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Tipranks
Novartis AG (NOVN) Gets a Buy from Kepler Capital
Tipranks
VYMI vs. VIG vs. VYM: Which Vanguard Dividend ETF Pays You Most?
Motley Fool
Legend Biotech (LEGN) Q4 2024 Earnings Transcript
Tipranks
Goldman Sachs Keeps Their Sell Rating on Novartis AG (NOVN)
Zacks Investment Research
TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
Zacks Investment Research
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
Tipranks
Citi Reaffirms Their Buy Rating on Novartis AG (NOVN)
Tipranks
Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)
Newswire.ca
Novartis Canada Reopens NOYCIA 2026, Continuing Its Longstanding Investment in the Future of Oncology Research
Zacks Investment Research
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
Tipranks
Novartis AG (NOVN) Receives a Hold from Barclays
Baystreet
Pharma Giant Novartis Buys Biotech Firm Excellergy For $2 Billion
Motley Fool
International ETFs: EEM and IEFA Offer Distinct Global ETF Choices
Zacks Investment Research
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
Tipranks
Novartis AG (NOVN) Gets a Buy from Deutsche Bank
Motley Fool
Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF
Tipranks
Novartis AG (NOVN) Receives a Hold from UBS
Tipranks
Barclays Reaffirms Their Hold Rating on Novartis AG (NOVN)
Motley Fool
3 ETFs Built for the Volatile Market We're Seeing in March 2026
Tipranks
Goldman Sachs Sticks to Their Sell Rating for Novartis AG (NOVN)
Tipranks
Novartis (NVS) Receives a New Rating from Bernstein
Zacks Investment Research
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
Tipranks
Novartis Raises $11 Billion in Multi-Tranche U.S. Bond Offering
Motley Fool
VYMI: This International ETF Could Help You Earn Higher Dividends
MarketBeat
3 ETFs to Avoid as Oil Shock Hits Markets
MarketBeat.com

Profile

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.